1. I am bullish on Nvidia's growth prospects due to healthy RPO growth, a 3.2% growth increment from Stargate demand, and encouraging growth signals from a key supplier; 2. Gross margins are expected to dip in Q1 FY26, but management's assurance of a rebound later is trusted; 3. TSMC's tariff avoidance benefits NVDA, but receivable days and tariff risks are concerns; 4. NVDA's valuations are attractive, but technical charts suggest waiting for a buy signal.

1. Medical Properties Trust faces regular impairments and cash flow issues. 2. High leverage and fixed interest rates limit benefits from potential rate cuts. 3. Operational weaknesses and declining revenues signal a potential value trap despite low valuations.